Literature DB >> 21270223

High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity.

Avelin F Aghokeng1, Eitel Mpoudi-Ngole, Julius E Chia, Elvine M Edoul, Eric Delaporte, Martine Peeters.   

Abstract

The ViroSeq HIV-1 genotyping system is used in many African countries for drug resistance testing. In this study, we used a panel of diverse HIV-1 group M isolates circulating in Cameroon to show that the performance of this assay can be altered by the sequence variation of non-B HIV-1 strains that predominate in African settings.

Entities:  

Mesh：

Year:  2011        PMID： 21270223      PMCID： PMC3122788          DOI： 10.1128/JCM.01478-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.

Authors: 
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

2.  Accuracy of the TRUGENE HIV-1 genotyping kit.

Authors:  Robert M Grant; Daniel R Kuritzkes; Victoria A Johnson; John W Mellors; John L Sullivan; Ronald Swanstrom; Richard T D'Aquila; Mark Van Gorder; Mark Holodniy; Robert M Lloyd; Caroline Reid; Gillian F Morgan; Dean L Winslow
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

3.  Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory.

Authors:  Bart Maes; Yoeri Schrooten; Joke Snoeck; Inge Derdelinckx; Marc Van Ranst; Anne-Mieke Vandamme; Kristel Van Laethem
Journal:  J Virol Methods       Date:  2004-07       Impact factor: 2.014

4.  Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.

Authors:  L Vergne; M Peeters; E Mpoudi-Ngole; A Bourgeois; F Liegeois; C Toure-Kane; S Mboup; C Mulanga-Kabeya; E Saman; J Jourdan; J Reynes; E Delaporte
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

5.  Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer.

Authors:  Susan H Eshleman; Gillian Crutcher; Olga Petrauskene; Kevin Kunstman; Shawn P Cunningham; Christina Trevino; Cheryl Davis; John Kennedy; Jeff Fairman; Brian Foley; Joann Kop
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

6.  Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire.

Authors:  Ebi C Bilé; Christiane Adjé-Touré; Marie-Yolande Borget; Mireille Kalou; Fabien Diomande; Terence Chorba; John N Nkengasong
Journal:  J Clin Virol       Date:  2005-01       Impact factor: 3.168

7.  Evaluation of the editing process in human immunodeficiency virus type 1 genotyping.

Authors:  Diana D Huang; Susan H Eshleman; Donald J Brambilla; Paul E Palumbo; James W Bremer
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination.

Authors:  K S Lole; R C Bollinger; R S Paranjape; D Gadkari; S S Kulkarni; N G Novak; R Ingersoll; H W Sheppard; S C Ray
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains.

Authors:  Susan H Eshleman; John Hackett; Priscilla Swanson; Shawn P Cunningham; Birgit Drews; Catherine Brennan; Sushil G Devare; Léopold Zekeng; Lazare Kaptué; Natalia Marlowe
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.

Authors:  Carole L Wallis; Maria A Papathanasopoulos; Shabir Lakhi; Etienne Karita; Anatoli Kamali; Pontiano Kaleebu; Eduard Sanders; Omu Anzala; Linda-Gail Bekker; Gwynn Stevens; Tobias F Rinke de Wit; Wendy Stevens
Journal:  J Virol Methods       Date:  2009-11-14       Impact factor: 2.014
View more
  11 in total

Review 1.  Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.

Authors:  Yi-Wei Tang; Chin-Yih Ou
Journal:  Emerg Microbes Infect       Date:  2012-08-22       Impact factor: 7.163

2.  Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance.

Authors:  Serge C Billong; Joseph Fokam; Avelin F Aghokeng; Pascal Milenge; Etienne Kembou; Ibile Abessouguie; Flore Beatrice Meva'a-Onglene; Anne C Zoung-Kanyi Bissek; Vittorio Colizzi; Eitel N Mpoudi; Jean-Bosco N Elat; Koulla S Shiro
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

3.  Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings.

Authors:  Zhiyong Zhou; Nick Wagar; Joshua R DeVos; Erin Rottinghaus; Karidia Diallo; Duc B Nguyen; Orji Bassey; Richard Ugbena; Nellie Wadonda-Kabondo; Michelle S McConnell; Isaac Zulu; Benson Chilima; John Nkengasong; Chunfu Yang
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

4.  Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.

Authors:  Dawn M Dudley; Adam L Bailey; Shruti H Mehta; Austin L Hughes; Gregory D Kirk; Ryan P Westergaard; David H O'Connor
Journal:  Retrovirology       Date:  2014-12-23       Impact factor: 4.602

5.  Development, validation and clinical evaluation of a low cost in-house HIV-1 drug resistance genotyping assay for Indian patients.

Authors:  Arpan Acharya; Salil Vaniawala; Parth Shah; Rabindra Nath Misra; Minal Wani; Pratap N Mukhopadhyaya
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

6.  Performance of an in-house human immunodeficiency virus type 1 genotyping system for assessment of drug resistance in Cuba.

Authors:  Yoan Alemán; Lore Vinken; Vivian Kourí; Lissette Pérez; Alina Álvarez; Yeissel Abrahantes; Carlos Fonseca; Jorge Pérez; Consuelo Correa; Yudira Soto; Yoeri Schrooten; Anne-Mieke Vandamme; Kristel Van Laethem
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

7.  Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays.

Authors:  Mohammad-Ali Jenabian; Frédéric Talla; Perrine Talla; François-Xavier Mbopi-Kéou; Charlotte Charpentier; Coumba Toure Kane; Laurent Bélec
Journal:  Niger Med J       Date:  2015 Nov-Dec

8.  PANDAA intentionally violates conventional qPCR design to enable durable, mismatch-agnostic detection of highly polymorphic pathogens.

Authors:  Iain J MacLeod; Christopher F Rowley; M Essex
Journal:  Commun Biol       Date:  2021-02-18

9.  LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa.

Authors:  Linda Chapdeleine Mekue Mouafo; Hélène Péré; Angélique Ndjoyi-Mbiguino; Donato Koyalta; Jean De Dieu Longo; François-Xavier Mbopi-Kéou; Coumba Toure Kane; Laurent Bélec
Journal:  Open AIDS J       Date:  2015-02-27

10.  Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.

Authors:  Kaelo K Seatla; Wonderful T Choga; Mompati Mogwele; Thabo Diphoko; Dorcas Maruapula; Lucy Mupfumi; Rosemary M Musonda; Christopher F Rowley; Ava Avalos; Ishmael Kasvosve; Sikhulile Moyo; Simani Gaseitsiwe
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.